Aug 19, 2020

A new partnership with Medis

Neurim Pharmaceuticals is proud to announce a new partnership with Medis. This exclusive marketing rights agreement for the commercialization of Slenyto will allow children and their families in the CEE region to access the new drug.

Slenyto is the first and only prescription medicine indicated for the treatment of insomnia in children and adolescents aged 2 to 18 years with (ASD Autism Spectrum Disorder) and/or Smith-Magenis syndrome for whom sleep hygiene measures have been inadequate. Slenyto is a paediatric prolonged-release melatonin formulation that uniquely mimics endogenous melatonin secretion.

The partnership agreement includes exclusive rights to promote the product in Austria, Croatia, Czech Republic, Hungary, Slovakia and Slovenia, leveraging Medis’ strong sales and marketing capabilities and experience in successfully bringing Neurim’s innovative medicines to the CEE region.